Purple Biotech Ltd. announced a collaboration with Converge Bio to leverage proprietary generative AI for accelerating development of its next-generation tri-specific antibody platform. The partnership aims to reduce discovery timelines, enhance molecule quality, and target solid tumors, building on the CAPTN-3 platform.
Key takeaways
Purple Biotech Ltd. (PPBT) collaborates with Converge Bio on AI-driven design and optimization of novel tri-specific antibodies
AI approach designed to significantly accelerate discovery timelines and improve candidate developability for solid tumor targets
Builds on CAPTN-3 platform, which generates masked tri-specific antibodies engaging T cells and NK cells
Converge Bio has completed over 40 AI programs with pharmaceutical and biotech companies
CAPTN-3 lead candidates IM1240 (targeting 5T4) and IM1305 (targeting TROP2) in preclinical development